Jasper Therapeutics: Bank of America reports 6.4% stake
The reported position is associated with shared voting and disposition powers; Bank of America reports no sole voting or disposition power.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. (JSPR) is the issuer in a beneficial-ownership report by Bank of America Corporation, which lists 2,133,861 Voting Common Stock shares, or 6.4% of the class. Bank of America reports shared voting and shared dispositive power over 2,133,861 shares, and zero sole voting and sole dispositive power.
The report is made by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., Bank of America, N.A., and Merrill Lynch International. The 6.4% calculation uses Jasper's 33,274,561 shares outstanding as of September 28, 2026, as disclosed in its DEFA14A on October 19, 2026.
Key Figures
Key Terms
beneficially owned regulatory
Sole Voting Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.